

Ref. No: 2735
Date: 03/08/26
Subject: Atopic Dermatitis

REQUEST

Question 1. How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Lebrikizumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib
- Nemolizumab

Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib
- Nemolizumab

*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen

Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5
- Age 6-11
- Age 12-17
- Age 18 and above

Question 4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:

- Dupilumab
- Nemolizumab

RESPONSE

Question 1. How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products:

- Abrocitinib 8
- Acitretin 19
- Alitretinoin 0
- Azathioprine 8
- Baricitinib 15
- Ciclosporin 9
- Dupilumab 157
- Lebrikizumab 11
- Methotrexate 543
- Mycophenolate mofetil 0
- Pimecrolimus 8
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only – unable to answer
- Tacrolimus ointment 136
- Tralokinumab 9
- Upadacitinib 22
- Nemolizumab <5

Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib n/a
- Baricitinib 0
- Dupilumab <5
- Lebrikizumab n/a

- Tralokinumab n/a
- Upadacitinib <5
- Nemolizumab n/a

*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen

Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5 - 0
- Age 6-11 - 6
- Age 12-17 - 42
- Age 18 and above - 902